Clinical Cancer Drugs,volume 3,issue 1  (03-2016)

Period of time： 2016年1期

Publisher： Bentham Science Publishers

Founded in： 2014

Total resources： 8

E-ISSN： 2212-6988|3|1

ISSN： 2212-697x

Subject： R9 Pharmacy

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Clinical Cancer Drugs,volume 3,issue 1

Menu

Preface:

Clinical Cancer Drugs,volume 3,issue 1 , Vol. 3, Iss. 1, 2016-03 , pp. 1-1

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Editorial (Thematic Issue: Novel Therapeutic Strategies for Castration-resistant Prostate Cancer: Update and Future Perspectives)

Clinical Cancer Drugs,volume 3,issue 1 , Vol. 3, Iss. 1, 2016-03 , pp. 2-5

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Prostate Cancer Molecular Background: The IGF-1Ec Story

Clinical Cancer Drugs,volume 3,issue 1 , Vol. 3, Iss. 1, 2016-03 , pp. 6-15

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Targeting Epigenome As An Innovative Pharmacological Strategy For Castration-resistant Prostate Cancer

Clinical Cancer Drugs,volume 3,issue 1 , Vol. 3, Iss. 1, 2016-03 , pp. 23-35

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs,volume 3,issue 1 , Vol. 3, Iss. 1, 2016-03 , pp. 36-62

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies

Clinical Cancer Drugs,volume 3,issue 1 , Vol. 3, Iss. 1, 2016-03 , pp. 63-73

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Total 6 item(s)